¿Â¿µ±Ù			 ¸íÀÇ

ºÎÁ¤¸Æ Ä¡·á¸¦ ¼±µµÇÏ´Â ¸íÀÇ

¿Â¿µ±Ù ¸íÀÇ

  • ¼Ò ¼Ó
    »ï¼º¼­¿ïº´¿ø
  • Áø·á°ú
    ¼øÈ¯±â³»°ú
  • Àü¹®ºÐ¾ß
    ºÎÁ¤¸Æ, ½Ç½Å, Àΰø½ÉÀå¹Úµ¿±â, ½É¹æ¼¼µ¿, ½ÉÀåµ¹¿¬»ç

¿Â¿µ±Ù ±³¼ö´Â ±¹³»¿¡¼­ ¼Õ²ÅÈ÷´Â ºÎÁ¤¸Æ Ä¡·áÀÇ ´ë°¡ÀÌ´Ù. ¿Â¿µ±Ù ±³¼ö´Â 2012³â ½ÉÀå¿Ü°ú Á¤µ¿¼· ±³¼ö¿Í ÇÔ²² ±¹³» ÃÖÃÊ·Î ÇÏÀ̺긮µå ºÎÁ¤¸Æ Ä¡·á¸¦ ¼±º¸ÀÎ °³Ã´ÀÚÀÌ´Ù. ÀÌ Ä¡·á¹ýÀº ³»°úÀû ½Ã¼ú°ú ¿Ü°úÀû ¼ö¼úÀ» °áÇÕÇÏ¿©, Àç¹ßÀÌ ÀæÀº ½É¹æ¼¼µ¿ ºÎÁ¤¸ÆÀÇ Á¤»ó ¹Úµ¿ À¯ÁöÀ²À»È¹±âÀûÀ¸·Î ³ô¿´´Ù. ¶ÇÇÑ, 2024³â¿¡´Â ±¹³»¿¡¼­ óÀ½À¸·Î ÷´Ü ºÎÁ¤¸Æ Ä¡·á¹ýÀÎ ÆÞ½ºÀå ÀýÁ¦¼ú(PFA)À» ¼º°øÀûÀ¸·Î ½ÃµµÇß´Ù. 2023³â¿¡´Â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ ȸÀåÀ» ¸Ã¾Æ ±¹³» ÃÖÃÊ·Î ±¹Á¦½ÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ¸¦ À¯Ä¡ÇÏ´Â µî, ºÎÁ¤¸Æ Ä¡·á ¹× Çмú ¹ßÀü ºÐ¾ß¸¦ À̲ø°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ë ÀÇ´ë Çлç
  • ¼­¿ï´ë ÀÇ´ë ¼®»ç
  • ¼­¿ï´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Atrial fibrillation burden and symptom, quality of life, and healthcare resource utilization after cryoballoon ablation in persistent atrial fibrillation
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Europace
Á¦ ¸ñ Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Journal of Clinical Medicine
Á¦ ¸ñ First-Pass Isolation as an Independent Predictor of Atrial Fibrillation Recurrence After Cryoballoon Ablation in Patients with Persistent Atrial Fibrillation
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö Journal of Clinical Medicine
Á¦ ¸ñ Ablation therapy following unsuccessful electrical cardioversion in patients with persistent atrial fibrillation
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Scientific Reports
Á¦ ¸ñ Optimal Dose of Edoxaban for Very Elderly Atrial Fibrillation Patients at High Risk of Bleeding: The LEDIOS Registry
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Korean Circulation Journal
Á¦ ¸ñ Long-term outcome of thoracoscopic ablation and radiofrequency catheter ablation for persistent atrial fibrillation as a de novo procedure
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Europace
Á¦ ¸ñ Exercise capacity and risk of incident atrial fibrillation in healthy adults
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö The Korean Journal of Internal Medicine

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

»ï¼º¼­¿ïº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1599-3114

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

»ï¼º¼­¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.

»ï¼º¼­¿ïº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­³²±¸ ÀÏ¿ø·Î 81

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä